Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
To be competitive in plaque psoriasis, Pfizer’s Xeljanz may need its higher dose – but it will have to convince FDA to approve a dose it rejected due to safety concerns in rheumatoid arthritis.